Literature DB >> 8542111

Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome.

T Fuchs-Buder1, P de Moerloose, B Ricou, G Reber, C Vifian, L Nicod, J A Romand, P M Suter.   

Abstract

Intraalveolar fibrin deposition is a typical finding in acute lung injury and is not necessarily harmful. However, persistence of intraalveolar fibrin deposit may lead to hyaline membrane formation and subsequent alveolar fibrosis, a histologic hallmark of late stages of acute respiratory distress syndrome (ARDS). Thus, timing of the intraalveolar clotting disorder seems to be critical. To explore the time course of factors contributing to fibrin deposition and resolution, we sequentially analyzed procoagulant activity and fibrin degradation (by D dimer) in bronchoalveolar lavage (BAL) fluid of patients developing ARDS and those at risk for, but finally not developing, the syndrome. A total of 36 bronchoalveolar lavages were performed in 11 patients developing ARDS and 15 lavages in 10 patients at risk for but not developing this syndrome. All patients were admitted to the intensive care unit for the treatment of sepsis, trauma, or shock. In early phases of ARDS, the procoagulant activity (PCA) in BAL was significantly higher than in the patients at risk, 320 +/- 83 U (mean +/- SEM) versus 50 +/- 25 U, p < 0.05. A similar difference was noted in subacute stages (280 +/- 91 versus 46 +/- 16 U, p < 0.05). In early ARDS we observed higher levels of D dimer in BAL than in patients at risk: 1,841 +/- 827 versus 293 +/- 134 ng/ml, p < 0.05. Similarly, values of D dimer in the subacute phase were 2,776 +/- 836 versus 237 +/- 125 ng/ml, p < 0.05. In ARDS as well as in the at-risk group, D dimer in BAL fluid showed good correlation with the polymorphonuclear leukocyte count and with protein content of BAL. There was no correlation between plasma and BAL levels of D dimer. We conclude that in ARDS both the procoagulant pathway and the fibrin degradation are markedly activated compared with these in patients at risk but finally not developing this syndrome. These findings expand our understanding of intraalveolar coagulation abnormalities by providing evidence of increased fibrin breakdown in this syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8542111     DOI: 10.1164/ajrccm.153.1.8542111

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  22 in total

1.  Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.

Authors:  Jean-Christophe Richard; Fabienne Bregeon; Véronique Leray; Didier Le Bars; Nicolas Costes; Christian Tourvieille; Franck Lavenne; Mojgan Devouassoux-Shisheboran; Gerard Gimenez; Claude Guerin
Journal:  Intensive Care Med       Date:  2007-08-02       Impact factor: 17.440

2.  Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury.

Authors:  Marcus J Schultz; Marcel Levi
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

Review 3.  Approach to the patient with the acute respiratory distress syndrome.

Authors:  David R Janz; Lorraine B Ware
Journal:  Clin Chest Med       Date:  2014-09-26       Impact factor: 2.878

4.  Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs in vivo.

Authors:  C Cicala; M Bucci; G De Dominicis; P Harriot; L Sorrentino; G Cirino
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

5.  Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury.

Authors:  R Gisli Jenkins; Xiao Su; George Su; Christopher J Scotton; Eric Camerer; Geoffrey J Laurent; George E Davis; Rachel C Chambers; Michael A Matthay; Dean Sheppard
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

Review 6.  Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome.

Authors:  Sara C Sebag; Julie A Bastarache; Lorraine B Ware
Journal:  Curr Pharm Biotechnol       Date:  2011-09       Impact factor: 2.837

7.  Early coagulation events induce acute lung injury in a rat model of blunt traumatic brain injury.

Authors:  Hideki Yasui; Deborah L Donahue; Mark Walsh; Francis J Castellino; Victoria A Ploplis
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-05-17       Impact factor: 5.464

Review 8.  Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies.

Authors:  Jenny Juschten; Pieter R Tuinman; Nicole P Juffermans; Barry Dixon; Marcel Levi; Marcus J Schultz
Journal:  Ann Transl Med       Date:  2017-11

Review 9.  Gene Therapy for Acute Respiratory Distress Syndrome.

Authors:  Jing Liu; David A Dean
Journal:  Front Physiol       Date:  2022-01-17       Impact factor: 4.566

10.  Increased cardiac index due to terbutaline treatment aggravates capillary-alveolar macromolecular leakage in oleic acid lung injury in dogs.

Authors:  Raphael Briot; Sam Bayat; Daniel Anglade; Jean-Louis Martiel; Francis Grimbert
Journal:  Crit Care       Date:  2009-10-21       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.